Collectively, our in vivo and in vitro studies indicate that hypertension promotes more skeletal muscle fibrosis, and AngII-AT1a signaling is the main pathway of fibrosis in SHR, and muscle fibrosis can be specifically treated with in loco injection of Lv-mirAT1a without affecting other organs. The gene discussed is AGT; the disease is hypertensive disorder.